June 8, 2016—A Senate committee investigating sky-high pricing on age-old medicines wants five drugmakers to explain why an opioid overdose rescue drug’s cost is rising.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)